What are the precautions when discontinuing baricitinib/baricitinib?

Discontinuation of baricitinib (Baricitinib) needs to be done with caution under the guidance of a physician, especially in patients who are used to control chronic immune diseases such as rheumatoid arthritis and alopecia areata . Sudden discontinuation may lead to a rapid increase in disease activity and trigger a rebound of symptoms. Since baricitinib acts on the JAK1 and JAK2 signaling pathways, long-term use can inhibit the activity of multiple cytokines. Once interrupted, the original inflammatory state may relapse rapidly, especially in patients whose disease has not yet stabilized or has not yet achieved complete remission. Therefore, a systematic assessment, including joint symptoms, laboratory indicators, and past drug reactions, needs to be conducted before discontinuation of medication. If necessary, alternative treatment plans should be formulated in advance, such as transitioning to other appropriate immunomodulators.

Common clinical reasons for discontinuation include infection, abnormal liver and kidney function, preoperative preventive measures, or discontinuation of medication due to adverse reactions. In cases of infection or preparation for major surgery, doctors may recommend holding baricitinib for a few days or longer due to safety concerns. At this time, changes in the condition should be closely monitored and medication should be avoided to avoid inducing potential complications. In addition, baricitinib can affect white blood cell and platelet counts. If significant abnormalities are found during monitoring, it is also necessary to evaluate whether to reduce the dose or discontinue the drug. During the withdrawal process, patients may experience reactions such as fatigue and increased pain in the short term. This is a "rebound effect" after the immune suppression is lifted, but it does not mean that the condition is uncontrollable.

It is worth emphasizing that the decision to discontinue medication should be made on an individual basis, and doctors will make a judgment based on the patient's disease stability, medication history, and potential risks. Some patients may try to discontinue medication while in remission to observe whether they can maintain their asymptomatic state, but long-term follow-up is required to assess the risk of recurrence. Therefore, patients should not adjust their treatment without authorization before stopping baricitinib, and should ensure adequate communication between doctors and patients to ensure that treatment continuity and long-term effects are not affected.

Reference materials:https://go.drugbank.com/drugs/DB11817